Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 10-Q Quarterly Report
Day One Biopharmaceuticals, Inc. (DAWN) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Day One Biopharmaceuticals, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New licensing risk: Acquisition of DAY301 license from MabCare Therapeutics in June 2024 adds development and commercialization uncertainties
- • Updated financial risk: Net loss increased to $86.0 million for nine months ended Sept 30, 2025 vs $29.8 million prior year, reflecting higher R&D and commercialization costs
- • Regulatory risk: FDA approved OJEMDA in April 2024 for pLGG with BRAF mutations; post-marketing commitments and potential requirements pose ongoing compliance risks
- • Operational risk: Early commercialization stage with challenges in manufacturing scale-up, sales, marketing, and supply chain for OJEMDA and DAY301
- • Liquidity risk: $451.6 million cash and equivalents as of Sept 30, 2025, sufficient for at least 12 months; future capital needs depend on clinical progress and market conditions
Day One Biopharmaceuticals, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$40M
▼ -61.0% YoY▲ +17.4% QoQ
Net Income
-$20M
▼ -153.3% YoY▲ +34.9% QoQ
Operating Margin
-60.9%
▼ -9001bp YoY▲ +4220bp QoQ
Net Margin
-49.6%
▼ -8590bp YoY▲ +3986bp QoQ
ROE
-4.4%
Total Assets
$514M
EPS (Diluted)
$-0.19
▼ -143.2% YoY▲ +34.5% QoQ
Operating Cash Flow
-$6M
▼ -111.4% YoY▲ +76.6% QoQ
Source: XBRL data from Day One Biopharmaceuticals, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Day One Biopharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.